Eton Pharmaceuticals (ETON) Cash from Financing Activities (2019 - 2025)

Eton Pharmaceuticals has disclosed Cash from Financing Activities across 7 years of filings, most recently posting $421000.0 for Q4 2025.

• In Q4 2025, Cash from Financing Activities fell 98.75% year-over-year to $421000.0; the TTM figure through Dec 2025 stood at $815000.0 (down 97.5% YoY), while the FY2025 annual figure was $815000.0, down 97.5% from the prior year.
• Cash from Financing Activities came in at $421000.0 for Q4 2025 at Eton Pharmaceuticals, up from $394000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $33.6 million in Q4 2024 to a low of -$385000.0 in Q1 2022.
• Average Cash from Financing Activities over 5 years is $1.8 million, with a median of -$7000.0 recorded in 2022.
• Year-over-year, Cash from Financing Activities tumbled 1154.29% in 2023 and surged 11519.05% in 2024.
• Over 5 years, Cash from Financing Activities stood at $68000.0 in 2021, then soared by 45.59% to $99000.0 in 2022, then slumped by 396.97% to -$294000.0 in 2023, then surged by 11519.05% to $33.6 million in 2024, then tumbled by 98.75% to $421000.0 in 2025.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $421000.0 in Q4 2025, $394000.0 in Q1 2025, and $33.6 million in Q4 2024.